Type of manuscript: Original Research Article

Improving Assessment of Vaccine Effectiveness by Coupling Test-Negative Design Studies with Survival Models

Shangchen Song[1], Matt Hitchings[1, 2], Yang Yang[3, #], Ira M. Longini, Jr.[1, #, *], on behalf of the N3C consortium[†]

[1] Department of Biostatistics, College of Public Health and Health Professions, University of Florida, Gainesville, FL, USA

[2] Emerging Pathogens Institute, University of Florida, Gainesville, USA.

[3] Department of Statistics, Franklin College of Arts and Sciences, University of Georgia, Athens, GA, USA

[#] These authors share senior authorship
[†] Consortial contributors are in the process of being documented

*** Correspondence should be addressed to:**
Prof. Ira M. Longini, Jr.
Phone: +1 (352) 294-1938
Email: ilongini@ufl.edu
Address: 228 Buckman Dr 452, Dauer Hall, Gainesville, FL, USA, 32611

Running Head

Test-Negative Design with Survival Models

Conflicts of Interest

None declared.

Funding/Support

SS, YY and IL were supported by US CDC grant U01 CK000670.

Role of the Funding Source

The funders had no role in study design, data collection, data analysis, data interpretation, or the writing of the report.

Data Sharing

Simulation codes are available on the GitHub repository at https://github.com/songuf/TND-Survival. Access to the N3C data analysis codes and data is provided through the N3C Data Enclave for users who have an approved protocol and a data use request from an institutional review board. Additional details on accessing the N3C data is provided on https://covid.cd2h.org/enclave/.

Ethics Approval

This study was deemed exempt by the University of Florida institutional review board (IRB202301849), which was accepted by N3C Data Access Committee (DUR- RP-7FEF96). The N3C data transfer to NCATS is performed under a Johns Hopkins University Reliance Protocol # IRB00249128 or individual site agreements with NIH. The N3C Data Enclave is managed under the authority of the NIH; information can be found at https://ncats.nih.gov/n3c/resources.

Acknowledgement

Authorship was determined using ICMJE recommendations.

The real data analysis described in this publication were conducted with data or tools accessed through the NCATS N3C Data Enclave https://covid.cd2h.org and N3C Attribution & Publication Policy v 1.2-2020-08-25b supported by NCATS U24 TR002306. This research was possible because of the patients whose information is included within the data and the organizations (https://ncats.nih.gov/n3c/resources/data-contribution/data-transfer-agreement-signatories) and scientists who have contributed to the on-going development of this community resource [https://doi.org/10.1093/jamia/ocaa196].

The N3C Publication committee confirmed that this manuscript msid:2339.618 is in accordance with N3C data use and attribution policies; however, this content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the N3C program.

We gratefully acknowledge the following core contributors to N3C: Adam B. Wilcox, Adam M. Lee, Alexis Graves, Alfred (Jerrod) Anzalone, Amin Manna, Amit Saha, Amy Olex, Andrea Zhou, Andrew E.

Williams, Andrew M. Southerland, Andrew T. Girvin, Anita Walden, Anjali Sharathkumar, Benjamin Amor, Benjamin Bates, Brian Hendricks, Brijesh Patel, G. Caleb Alexander, Carolyn T. Bramante, Cavin Ward-Caviness, Charisse Madlock-Brown, Christine Suver, Christopher G. Chute, Christopher Dillon, Chunlei Wu, Clare Schmitt, Cliff Takemoto, Dan Housman, Davera Gabriel, David A. Eichmann, Diego Mazzotti, Donald E. Brown, Eilis Boudreau, Elaine L. Hill, Emily Carlson Marti, Emily R. Pfaff, Evan French, Farrukh M Koraishy, Federico Mariona, Fred Prior, George Sokos, Greg Martin, Harold P. Lehmann, Heidi Spratt, Hemalkumar B. Mehta, J.W. Awori Hayanga, Jami Pincavitch, Jaylyn Clark, Jeremy Richard Harper, Jessica Yasmine Islam, Jin Ge, Joel Gagnier, Johanna J. Loomba, John B. Buse, Jomol Mathew, Joni L. Rutter, Julie A. McMurry, Justin Guinney, Justin Starren, Karen Crowley, Katie Rebecca Bradwell, Kellie M. Walters, Ken Wilkins, Kenneth R. Gersing, Kenrick Cato, Kimberly Murray, Kristin Kostka, Lavance Northington, Lee Pyles, Lesley Cottrell, Lili M. Portilla, Mariam Deacy, Mark M. Bissell, Marshall Clark, Mary Emmett, Matvey B. Palchuk, Melissa A. Haendel, Meredith Adams, Meredith Temple-O'Connor, Michael G. Kurilla, Michele Morris, Nasia Safdar, Nicole Garbarini, Noha Sharafeldin, Ofer Sadan, Patricia A. Francis, Penny Wung Burgoon, Philip R.O. Payne, Randeep Jawa, Rebecca Erwin-Cohen, Rena C. Patel, Richard A. Moffitt, Richard L. Zhu, Rishikesan Kamaleswaran, Robert Hurley, Robert T. Miller, Saiju Pyarajan, Sam G. Michael, Samuel Bozzette, Sandeep K. Mallipattu, Satyanarayana Vedula, Scott Chapman, Shawn T. O'Neil, Soko Setoguchi, Stephanie S. Hong, Steven G. Johnson, Tellen D. Bennett, Tiffany J. Callahan, Umit Topaloglu, Valery Gordon, Vignesh Subbian, Warren A. Kibbe, Wenndy Hernandez, Will Beasley, Will Cooper, William Hillegass, Xiaohan Tanner Zhang.

The following institutions whose data is released or pending:

Available: Advocate Health Care Network — UL1TR002389: The Institute for Translational Medicine (ITM) • Aurora Health Care Inc — UL1TR002373: Wisconsin Network For Health Research • Boston University Medical Campus — UL1TR001430: Boston University Clinical and Translational Science Institute • Brown University — U54GM115677: Advance Clinical Translational Research (Advance-CTR) • Carilion Clinic — UL1TR003015: iTHRIV Integrated Translational health Research Institute of Virginia • Case Western Reserve University — UL1TR002548: The Clinical & Translational Science Collaborative of

Cleveland (CTSC) • Charleston Area Medical Center — U54GM104942: West Virginia Clinical and Translational Science Institute (WVCTSI) • Children's Hospital Colorado — UL1TR002535: Colorado Clinical and Translational Sciences Institute • Columbia University Irving Medical Center — UL1TR001873: Irving Institute for Clinical and Translational Research • Dartmouth College — None (Voluntary) Duke University — UL1TR002553: Duke Clinical and Translational Science Institute • George Washington Children's Research Institute — UL1TR001876: Clinical and Translational Science Institute at Children's National (CTSA-CN) • George Washington University — UL1TR001876: Clinical and Translational Science Institute at Children's National (CTSA-CN) • Harvard Medical School — UL1TR002541: Harvard Catalyst • Indiana University School of Medicine — UL1TR002529: Indiana Clinical and Translational Science Institute • Johns Hopkins University — UL1TR003098: Johns Hopkins Institute for Clinical and Translational Research • Louisiana Public Health Institute — None (Voluntary) • Loyola Medicine — Loyola University Medical Center • Loyola University Medical Center — UL1TR002389: The Institute for Translational Medicine (ITM) • Maine Medical Center — U54GM115516: Northern New England Clinical & Translational Research (NNE-CTR) Network • Mary Hitchcock Memorial Hospital & Dartmouth Hitchcock Clinic — None (Voluntary) • Massachusetts General Brigham — UL1TR002541: Harvard Catalyst • Mayo Clinic Rochester — UL1TR002377: Mayo Clinic Center for Clinical and Translational Science (CCaTS) • Medical University of South Carolina — UL1TR001450: South Carolina Clinical & Translational Research Institute (SCTR) • MITRE Corporation — None (Voluntary) • Montefiore Medical Center — UL1TR002556: Institute for Clinical and Translational Research at Einstein and Montefiore • Nemours — U54GM104941: Delaware CTR ACCEL Program • NorthShore University HealthSystem — UL1TR002389: The Institute for Translational Medicine (ITM) • Northwestern University at Chicago — UL1TR001422: Northwestern University Clinical and Translational Science Institute (NUCATS) • OCHIN — INV-018455: Bill and Melinda Gates Foundation grant to Sage Bionetworks • Oregon Health & Science University — UL1TR002369: Oregon Clinical and Translational Research Institute • Penn State Health Milton S. Hershey Medical Center — UL1TR002014: Penn State Clinical and Translational Science Institute • Rush University Medical Center — UL1TR002389: The Institute for Translational Medicine (ITM) • Rutgers, The State University of New Jersey —

UL1TR003017: New Jersey Alliance for Clinical and Translational Science • Stony Brook University — U24TR002306 • The Alliance at the University of Puerto Rico, Medical Sciences Campus — U54GM133807: Hispanic Alliance for Clinical and Translational Research (The Alliance) • The Ohio State University — UL1TR002733: Center for Clinical and Translational Science • The State University of New York at Buffalo — UL1TR001412: Clinical and Translational Science Institute • The University of Chicago — UL1TR002389: The Institute for Translational Medicine (ITM) • The University of Iowa — UL1TR002537: Institute for Clinical and Translational Science • The University of Miami Leonard M. Miller School of Medicine — UL1TR002736: University of Miami Clinical and Translational Science Institute • The University of Michigan at Ann Arbor — UL1TR002240: Michigan Institute for Clinical and Health Research • The University of Texas Health Science Center at Houston — UL1TR003167: Center for Clinical and Translational Sciences (CCTS) • The University of Texas Medical Branch at Galveston — UL1TR001439: The Institute for Translational Sciences • The University of Utah — UL1TR002538: Uhealth Center for Clinical and Translational Science • Tufts Medical Center — UL1TR002544: Tufts Clinical and Translational Science Institute • Tulane University — UL1TR003096: Center for Clinical and Translational Science • The Queens Medical Center — None (Voluntary) • University Medical Center New Orleans — U54GM104940: Louisiana Clinical and Translational Science (LA CaTS) Center • University of Alabama at Birmingham — UL1TR003096: Center for Clinical and Translational Science • University of Arkansas for Medical Sciences — UL1TR003107: UAMS Translational Research Institute • University of Cincinnati — UL1TR001425: Center for Clinical and Translational Science and Training • University of Colorado Denver, Anschutz Medical Campus — UL1TR002535: Colorado Clinical and Translational Sciences Institute • University of Illinois at Chicago — UL1TR002003: UIC Center for Clinical and Translational Science • University of Kansas Medical Center — UL1TR002366: Frontiers: University of Kansas Clinical and Translational Science Institute • University of Kentucky — UL1TR001998: UK Center for Clinical and Translational Science • University of Massachusetts Medical School Worcester — UL1TR001453: The UMass Center for Clinical and Translational Science (UMCCTS) • University Medical Center of Southern Nevada — None (voluntary) • University of Minnesota — UL1TR002494: Clinical and Translational Science Institute • University of

Mississippi Medical Center — U54GM115428: Mississippi Center for Clinical and Translational Research (CCTR) • University of Nebraska Medical Center — U54GM115458: Great Plains IDeA-Clinical & Translational Research • University of North Carolina at Chapel Hill — UL1TR002489: North Carolina Translational and Clinical Science Institute • University of Oklahoma Health Sciences Center — U54GM104938: Oklahoma Clinical and Translational Science Institute (OCTSI) • University of Pittsburgh — UL1TR001857: The Clinical and Translational Science Institute (CTSI) • University of Pennsylvania — UL1TR001878: Institute for Translational Medicine and Therapeutics • University of Rochester — UL1TR002001: UR Clinical & Translational Science Institute • University of Southern California — UL1TR001855: The Southern California Clinical and Translational Science Institute (SC CTSI) • University of Vermont — U54GM115516: Northern New England Clinical & Translational Research (NNE-CTR) Network • University of Virginia — UL1TR003015: iTHRIV Integrated Translational health Research Institute of Virginia • University of Washington — UL1TR002319: Institute of Translational Health Sciences • University of Wisconsin-Madison — UL1TR002373: UW Institute for Clinical and Translational Research • Vanderbilt University Medical Center — UL1TR002243: Vanderbilt Institute for Clinical and Translational Research • Virginia Commonwealth University — UL1TR002649: C. Kenneth and Dianne Wright Center for Clinical and Translational Research • Wake Forest University Health Sciences — UL1TR001420: Wake Forest Clinical and Translational Science Institute • Washington University in St. Louis — UL1TR002345: Institute of Clinical and Translational Sciences • Weill Medical College of Cornell University — UL1TR002384: Weill Cornell Medicine Clinical and Translational Science Center • West Virginia University — U54GM104942: West Virginia Clinical and Translational Science Institute (WVCTSI) Submitted: Icahn School of Medicine at Mount Sinai — UL1TR001433: ConduITS Institute for Translational Sciences • The University of Texas Health Science Center at Tyler — UL1TR003167: Center for Clinical and Translational Sciences (CCTS) • University of California, Davis — UL1TR001860: UCDavis Health Clinical and Translational Science Center • University of California, Irvine — UL1TR001414: The UC Irvine Institute for Clinical and Translational Science (ICTS) • University of California, Los Angeles — UL1TR001881: UCLA Clinical Translational Science Institute • University of California, San Diego — UL1TR001442: Altman

Clinical and Translational Research Institute • University of California, San Francisco — UL1TR001872: UCSF Clinical and Translational Science Institute NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core — OTA-21-015A: Post-Acute Sequelae of SARS-CoV-2 Infection Initiative (RECOVER) Pending: Arkansas Children's Hospital — UL1TR003107: UAMS Translational Research Institute • Baylor College of Medicine — None (Voluntary) • Children's Hospital of Philadelphia — UL1TR001878: Institute for Translational Medicine and Therapeutics • Cincinnati Children's Hospital Medical Center — UL1TR001425: Center for Clinical and Translational Science and Training • Emory University — UL1TR002378: Georgia Clinical and Translational Science Alliance • HonorHealth — None (Voluntary) • Loyola University Chicago — UL1TR002389: The Institute for Translational Medicine (ITM) • Medical College of Wisconsin — UL1TR001436: Clinical and Translational Science Institute of Southeast Wisconsin • MedStar Health Research Institute — None (Voluntary) • Georgetown University — UL1TR001409: The Georgetown-Howard Universities Center for Clinical and Translational Science (GHUCCTS) • MetroHealth — None (Voluntary) • Montana State University — U54GM115371: American Indian/Alaska Native CTR • NYU Langone Medical Center — UL1TR001445: Langone Health's Clinical and Translational Science Institute • Ochsner Medical Center — U54GM104940: Louisiana Clinical and Translational Science (LA CaTS) Center • Regenstrief Institute — UL1TR002529: Indiana Clinical and Translational Science Institute • Sanford Research — None (Voluntary) • Stanford University — UL1TR003142: Spectrum: The Stanford Center for Clinical and Translational Research and Education • The Rockefeller University — UL1TR001866: Center for Clinical and Translational Science • The Scripps Research Institute — UL1TR002550: Scripps Research Translational Institute • University of Florida — UL1TR001427: UF Clinical and Translational Science Institute • University of New Mexico Health Sciences Center — UL1TR001449: University of New Mexico Clinical and Translational Science Center • University of Texas Health Science Center at San Antonio — UL1TR002645: Institute for Integration of Medicine and Science • Yale New Haven Hospital — UL1TR001863: Yale Center for Clinical Investigation

ABSTRACT

The test-negative design (TND) has become a widely used observational study design for evaluating vaccine effectiveness (VE), especially during the COVID-19 pandemic. Traditionally, TND has often been viewed as a variant of the case-control study, with its analysis largely limited to logistic regression models. In this paper, we first establish that TND can be framed as a special case of a cohort study, thereby opening the door to a wider range of analytical approaches. We then introduce the Prentice, Williams, and Peterson gap-time (PWP-GT) frailty model as a novel method for analyzing TND data, accounting for recurrent infections and time-dependent vaccination status. Through extensive simulation studies, we demonstrate that the proposed model outperforms conventional models commonly applied in TND-based VE studies. Finally, we apply our method to data from the National COVID Cohort Collaborative (N3C), estimating the effectiveness of full and booster doses of Pfizer's COVID-19 vaccines against both initial infection and reinfection during the Omicron variant circulation period in a real-world setting.

Keywords: test-negative design; survival analysis; COVID-19; vaccine effectiveness; recurrent infection

Introduction

The test-negative design (TND) is an observational study design increasingly used to evaluate vaccine effectiveness (VE), particularly for seasonal influenza [1] and more recently during the COVID-19 pandemic [2,3]. It has been instrumental in assessing post-licensure VE against SARS-CoV-2 in a real-world setting [4]. The TND became a preferred approach during the global public health emergency due to its cost-effectiveness, rapid implementation, and ability to be integrated into existing surveillance systems [5]. Additionally, the TND helps reduce the risk of misclassification bias by confirming the infection status through highly accurate laboratory tests. More importantly, it inherently adjusts for biases related to differential healthcare-seeking behavior (HSB) between vaccine recipients and non-recipients. Such differences in HSB are often challenging to measure in other study designs [6–8].

In the literature [2,9–11], the TND is often regarded as a type of case-control study and labeled as a "test-negative case-control study." Within this framework, logistic regression is typically employed as the primary method to compute the adjusted VE. For example, all 42 TND studies included in a recent meta-analysis [3] used either conditional or unconditional logistic regression models. However, relying solely on logistic regression for TND data can present certain limitations. Logistic regression is designed for binary outcomes and is not well-suited for time-to-event outcomes or addressing dropouts, leading to some loss of information. Furthermore, logistic regression does not provide a natural framework for modeling recurrent infections and time-varying vaccination status which are common during infectious disease outbreaks. Previous work including Sullivan et al. (2016) [6], Jackson et al. (2013) [7], and Sullivan et al. (2023) [12] has highlighted directly or indirectly that the TND may be viewed as cohort-like within the subpopulation of symptomatic, tested care-seekers. Shi et al. (2023) [8] discussed the potential of time-to-event models for analyzing TND data, based on some theoretical justification for application of such models to case-control studies [13].

In this work, we first demonstrate that the TND can be treated as a special case of cohort study, allowing for broader analytic methods beyond logistic regression, followed by an introduction to the Prentice, Williams, and Peterson gap-time (PWP-GT) frailty model and its applicability to the analysis of TND data, especially when recurrent infections exist. Previous studies [14–16] indicated that prior infection history or hybrid

immunity (prior infection + vaccine) provide more protection than vaccine alone for SARS-CoV-2 variants. Similarly, for influenza, vaccine immunogenicity was improved by prior infection than prior vaccination [17–19]. These findings motivated our consideration of recurrent infections when estimating vaccine effectiveness. Next, we conduct a series of simulations to compare the performance of the proposed method against existing models used in TND studies. Finally, we apply the proposed method to the National COVID Cohort Collaborative (N3C) datasets to estimate VE in a real-world setting.

Methods

Background of TND

A TND study usually begins by identifying a population, often geographically defined, where the pathogen of interest is actively circulating, and some individuals have received the vaccine under study. At the testing facilities within this population, as illustrated in Figure 1, patients presenting relevant clinical symptoms are recruited if they are tested for the pathogen of interest. These patients are then divided into two groups: those who test positive for the pathogen are categorized as "cases", while those who test negative become the "controls", assuming their symptoms are attributable to other co-circulating pathogens on which the vaccine has no effect.



Figure 1 Sampling and testing of the TND. In a population, the testing due to target symptoms acts like a lasso to capture the individuals over time. The infection status is ascertained only after an individual is recruited.

The VE is subsequently calculated using the formula $\mathrm{VE} = 1 - \mathrm{OR}$, where OR is the odds ratio (OR) of vaccination between cases and controls. This OR is usually adjusted for key confounders using unconditional logistic regression. Alternatively, if there are enough cases and controls, matching can be

applied to reduce confounding by pairing or stratifying them based on similar characteristics. In this situation, conditional logistic regression is used, which is closely related to the Cox regression model when matching is based on infection time [20]. The validity of TND relies on two important assumptions: (1) among individuals who present with the clinical syndrome eligible for enrollment, the probability of being tested for the target pathogen does not depend on which pathogen actually caused the symptoms; and (2) the vaccine of interest has no biological effect or social effect on nuisance pathogens causing similar symptoms as the pathogen of interest, where the social effect means that people vaccinated against the target pathogen are more likely to be vaccinated against nuisance pathogens. Let infection status be denoted by I, symptom status by S, vaccination status by V, and testing by T. Here symptom status refers to symptoms that need medical attention. We use subscript as a shorthand for the value of each symbol, e.g., V_0 ($V = 0$) and V_1 ($V = 1$) indicating unvaccinated and vaccinated, respectively. Unlike other symbols, I_0 here should be interpreted as infection by a nuisance pathogen, instead of no infection at all. In a simple setting of TND where the outcome is binary and confounders are suppressed, the VE is estimated by

$$VE = 1 - OR = 1 - \frac{P(V_1|I_1,S_1,T_1)/P(V_0|I_1,S_1,T_1)}{P(V_1|I_0,S_1,T_1)/P(V_0|I_0,S_1,T_1)}$$

Following the natural data-generating process of vaccination, infection, symptom onset, and testing, we can expand the OR as

$$\text{OR}=\frac{P(V_1|I_1,S_1,T_1)/P(V_0|I_1,S_1,T_1)}{P(V_1|I_0,S_1,T_1)/P(V_0|I_0,S_1,T_1)} = \frac{P(V_1,I_1,S_1,T_1)/P(V_0,I_1,S_1,T_1)}{P(V_1,I_0,S_1,T_1)/P(V_0,I_0,S_1,T_1)} =$$

$$\frac{[P(V_1)P(I_1,S_1|V_1)P(T_1|V_1,I_1,S_1)][P(V_0)P(I_0,S_1|V_0)P(T_1|V_0,I_0,S_1)]}{[P(V_1)P(I_0,S_1|V_1)P(T_1|V_1,I_0,S_1)][P(V_0)P(I_1,S_1|V_0)P(T_1|V_0,I_1,S_1)]} = \frac{[P(I_1,S_1|V_1)P(T_1|V_1,I_1,S_1)][P(I_0,S_1|V_0)P(T_1|V_0,I_0,S_1)]}{[P(I_0,S_1|V_1)P(T_1|V_1,I_0,S_1)][P(I_1,S_1|V_0)P(T_1|V_0,I_1,S_1)]} = \frac{P(I_1,S_1|V_1)}{P(I_1,S_1|V_0)}$$

where the last equation follows from $P(T_1|V_1, I_1, S_1) = P(T_1|V_1, I_0, S_1)$ and $P(T_1|V_0, I_1, S_1) = P(T_1|V_0, I_0, S_1)$ by assumption (1) and $P(I_0, S_1|V_0) = P(I_0, S_1|V_1)$ by assumption (2). It should be noted that there is no need to assume that the probability of testing is not affected by vaccination status. Interestingly, the OR in the TND turns into a relative risk (RR) in the population sense, which meets the standard definition of VE=1-RR. It is also clear that VE estimates from TND studies should be interpreted as vaccine effectiveness against

medically-attended symptomatic infections, which is particularly valuable as it reflects the burden on healthcare systems [21,22].

Rethinking the TND study: From case-control-like to cohort-like

The fundamental difference between case-control and cohort studies lies in the sampling of subjects. In cohort studies, participants are selected based on exposure (e.g., vaccination status in vaccine studies) or randomly from the population. In contrast, case-control studies select participants based on their outcome (e.g., infection status). The data distribution in cohort studies is represented as either $P(I|V)$ or $P(I,V)$, while in case-control studies it is $P(V|I)$.

Although TND studies are often viewed as case-control studies, they more closely resemble cohort studies. In a TND study, the outcome (infection status) is not used for recruitment but is determined only after participants are enrolled. This differentiates it from typical case-control studies, as well as nested case-control studies, unless post-hoc subsampling or matching is performed. In TND studies, participants are randomly sampled from individuals who seek testing for a pathogen due to relevant symptoms, representing a conditioned subset of the population. The data distribution in TND studies is represented by $P(I|V,S_1,T_1)$ or $P(V,I|S_1,T_1)$. Therefore, a TND study can be viewed as a conditioned cohort study, or alternatively, as a regular cohort study within a subpopulation. This argument can be further supported by re-writing the above OR as

$$\text{OR}=\frac{P(V_1,I_1,S_1,T_1)/P(V_0,I_1,S_1,T_1)}{P(V_1,I_0,S_1,T_1)/P(V_0,I_0,S_1,T_1)}=\frac{[P(V_1,S_1,T_1)P(I_1|V_1,S_1,T_1)][P(V_0,S_1,T_1)P(I_0|V_0,S_1,T_1)]}{[P(V_1,S_1,T_1)P(I_0|V_1,S_1,T_1)][P(V_0,S_1,T_1)P(I_1|V_0,S_1,T_1)]}=\frac{P(I_1|V_1,S_1,T_1)}{P(I_1|V_0,S_1,T_1)}$$

where we utilized assumption (2) again, $P(I_0|V_0,S_1,T_1)=P(I_0|V_1,S_1,T_1)$. If $P(I_1|V_1,S_1,T_1)$ and $P(I_1|V_0,S_1,T_1)$ imitate population level probabilities, we can analyze the TND data as a conditional cohort, using statistical models commonly used for cohort studies such as survival models. This is equivalent to requiring $P(I_1,V_1|S_1,T_1)$ and $P(I_1,V_0|S_1,T_1)$, and ultimately $P(I_1|S_1,T_1)$ and $P(I_0|S_1,T_1)$, to be similar to the population level proportions. Clearly, only TND studies that used all or a random sample of tested patients satisfy this requirement, whereas those matching each test-positive patient with a prespecified number of test-negative ones do not.

Relationship among the TND, the cohort study design, and the nested case-control study design

In nested case–control (NCC) studies, a cohort is predefined, and a subset of at-risk controls is sampled at each case time, together with the case, to form the at-risk set for that time point. Either conditional logistic regression or Cox regression can be used to estimate odds ratios or hazard ratios (HR) associated with risk factors including vaccination. If the sampling weights are known, baseline hazard can also be reliably estimated. If the sampling probability is 1, then the NCC is equivalent to the cohort study design. Hence, cohort study is a special case of NCC. A typical TND is a special (or conditional) cohort study restricted to the subpopulation who will seek healthcare and get tested if they become ill during the study period. With TND, enrollment occurs at care□seeking and testing regardless of the potential test result, and infection status is ascertained after enrollment. If a subset of test-negative controls is sampled to measure exposure history, referred to as a case□density (time□matched) subsampling scheme, then TND is not a special cohort study anymore but still a special NCC. Here we focus on TND where exposure history is measured on all enrolled subjects, not the case□density subsampling scheme. Viewing TND as a conditional cohort allows us to fit survival models to estimate both hazard ratios and baseline hazards, while naturally accounting for (i) time□varying vaccination, (ii) recurrent infections via event□order strata (PWP□GT), and (iii) external calendar□time hazards. Estimation of baseline hazards is especially important when the model contains frailties to reflect heterogeneity in the baseline hazard across individuals or clusters (Therneau et al., 2003) [23].

PWP-GT Frailty Model

We proposed the Prentice, Williams, and Peterson gap-time (PWP-GT) frailty model, an extension of the Prentice, Williams, and Peterson model [24] and the frailty model [25] based on Cox regression [26], to directly account for recurrent infections and time-dependent vaccination status in TND studies. In comparison, recurrent infections are modeled as binary outcomes in logistic regression, with previous infections and

vaccination status treated as indicator covariates at pre-specified time points, resulting in loss of the data information [27].

The PWP-GT frailty model handles the recurrent infections by assuming that a subject is not at risk for the sth infection until they have experienced the $(s-1)^{\text{th}}$ infection. Data associated with different infections are assigned into separate strata, each corresponding to a distinct infection. Therefore, this model provides more flexibility in allowing distinct baseline hazard and coefficients of covariates for each infection. The PWP-GT frailty model further assumes that the baseline hazard depends on the elapsed time since the previous infection—hence the term "gap-time"—rather than the total time from initial risk exposure. This accounts for subject-specific changes in internal immunity due to sequential infections. To complement internal factors, external risk can be incorporated into the model by adjusting for case numbers across different calendar time periods. Additionally, because multiple infections in a subject introduce significant within-subject correlation, the PWP-GT frailty model incorporates a frailty term to explicitly account for this dependency. Alternatively, a robust sandwich variance estimator [28] can be used instead of a frailty term to handle within-subject correlations, using a variance adjustment similar to generalized estimating equations (GEE) models [29]. When recurrent events are sparse, the frailty term can also be adapted to represent other correlation structures, such as the location of testing facilities. Finally, time-dependent covariates are used to model vaccination status, allowing the model to capture dynamic changes due to different doses or vaccination regimens.

Suppose a pathogen can cause up to S infections in a subject. The PWP-GT frailty model has the following hazard function $\lambda_{si}(t)$ for the ith subject against the sth infection.

$$\lambda_{si}(t) = \lambda_{0s}\left(t - t_{(s-1)i}\right)e^{\beta_s^T X_i(t)}\theta_i$$

where $\lambda_{0s}(t - t_{(s-1)i})$ is the baseline hazard for the sth infection at time $t - t_{(s-1)i}$ since the $(s-1)^{\text{th}}$ infection occurred to subject i, which is a shared term across all subjects who have experienced the $(s-1)^{\text{th}}$ infections. $X_i(t)$ is a vector of covariates for the ith subject at time t, which may include both time-dependent and time-independent variables affecting the hazard of the sth infection, and β_s is the associated vector of coefficients. θ_i is the frailty term, assumed to follow a Gamma distribution $\theta_i \sim \text{Gamma}(\alpha, \beta)$ with a mean of

1. The estimation and inference of the model parameters can be achieved by the penalized partial likelihood approach, which is implemented in standard statistical software packages, e.g., the *coxme* R package [30]. The VE estimate for s^{th} infection is given by $VE_s = 1 - \exp(\beta_s)$ if $X_i(t)$ indicates the vaccination status.

Simulation Studies

We conducted a series of hazard-based simulation studies to evaluate the performance of our proposed models in comparison to other commonly used VE estimation models in TND studies. Additionally, we examined the performance of the proposed models in a cohort study where HSB is not adequately controlled for, illustrating potential biases in VE estimates. The simulations considered both scenarios where VE remains constant over time and where it progressively wanes in a piecewise manner across short, medium, and long-term periods, with a specific focus on the performance of the PWP-GT frailty model under the second scenario which is more realistic for SARS-CoV-2 vaccines during the COVID-19 pandemic.

We investigated seven scenarios defined by combinations of study designs and analytic models in the simulation studies: (1) the PWP-GT frailty model in a TND study (PGF-TND), (2) the PWP-GT model with a robust sandwich variance estimator in a TND study (PGR-TND), (3) conditional logistic regression in a TND study (CL-TND), (4) unconditional logistic regression with adjustment for calendar time in a TND study (ULA-TND), (5) unconditional logistic regression without adjustment for calendar time in a TND study (UL-TND), (6) the PWP-GT frailty model in a cohort study (PGF-Cohort), and (7) the PWP-GT model with a robust sandwich variance estimator in a cohort study (PGR-Cohort).

We simulated 600 cohorts, each containing 30,000 participants. For each cohort, we first conducted a cohort study where all participants were followed longitudinally, with their vaccination and infection status tracked irrespective of whether they sought testing. Using the same cohort, we then simulated a TND study nested in the cohort, focusing only on individuals who sought testing due to symptoms caused by COVID-19 or other co-circulating respiratory pathogens. HSB, which influences both vaccination and infection, was simulated as an unmeasured variable that could not be included in the model. This introduced confounding bias in the cohort study, while in the TND study, this bias could be controlled by conditioning on testing at

facility. Supplementary Materials S.2 includes a Directed Acyclic Graph (Figure S1) illustrating this setup. Furthermore, our simulations only consider symptomatic infections, as TND studies primarily capture symptomatic cases.

In each simulation, a subset of individuals received a full dose of vaccine, and some of them further received a booster dose. Although a full course includes two partial doses separated by several weeks for most SARS-CoV-2 vaccines, for simplicity we did not consider the time gap between the partial doses in the simulation. Each individual might be subject to at most two infections. The VE against initial infection was set at 50% for full doses and 60% for the booster dose, while for reinfection, VE was set at 70% and 80%, respectively. A frailty term, following a $\mathrm{Gamma}(5, 0.2)$ distribution, was incorporated into the simulation for infection times. Detailed procedures for data generation and model implementation are provided in Supplementary Materials S.1 to S.2. The simulation codes are available on the GitHub repository at https://github.com/songuf/TND-Survival.

The simulation results across 600 cohorts are presented in Figure 2 including the average estimates of the four VE's, represented by asterisks, along with the (2.5%, 97.5%) quantile intervals (QI), represented by vertical bars, for the seven scenarios. The probability of the 95% confidence interval (CI) covering the true VE was shown beside each QI. Our analysis revealed that the PGF-TND achieves both minimal empirical bias relative to the true VE and the best CI coverage at the nominal level. The PGR-TND performed slightly worse than the PGF-TND, especially for the initial infection, suggesting that the robust sandwich estimator may not sufficiently address the within-subject correlation. The CL-TND showed more biases in the VE estimates and substantially worse CI coverage than the PGR-TND and PGF-TND. The performance of the ULA-TND was similar to that of the CL-TND for the full doses but slightly inferior for the booster dose. The UL-TND was associated with the most severe biases and nearly zero CI coverage probabilities, due to the fact that the unconditional odds ratio does not approximate the hazard ratio in the absence of adjustment for calendar time. In the context of cohort studies, both the PGF-Cohort and PGR-Cohort yield inflated VE estimates and poor CI coverage probabilities, due to their failure to control for the confounding effect of HSB. Supplementary Materials S.4 provides more detailed performance metrics.



Figure 2 Simulation results when VE remains constant over time: average VE estimates (asterisks) with (2.5%, 97.5%) quantile intervals (vertical bars) and 95% CI coverage probabilities (to the right of each QI) across 600 cohorts for the seven scenarios of study design and used model

We also simulated TND studies with VE that wanes over time as piecewise functions to assess the proposed PWP-GT frailty model under more realistic conditions. We considered solely the full doses against the initial infection and reinfection for simplicity. The VE was set to decline over every 3-months period, with 50% for the short term, 40% for the medium term, and 30% for the long term against the initial infection; and 80% for the short term, 70% for the medium term, and 60% for the long term against the reinfection. Additional details are available in Supplementary Materials S.3.

The simulation results for waning VE are shown in Figure 3. The dotted and dashed lines represent the trajectory of the true VE over time since vaccination. The asterisks represent the average, and the vertical error bars indicate the (2.5%, 97.5%) QIs of the VE estimates obtained by fitting the PWP-GT frailty model to 600 simulated datasets. The average estimates are very close to the true VE. The increasing uncertainty over time

in the VE estimates, particularly for the VE against the initial infection, is expected, as the number of infection events associated with long-term vaccination are relatively lower due to censoring of subsequent vaccination, infection and the end of study. The 95% confidence interval (CI) coverage probabilities, shown to the right of the QIs, are close to the nominal level. Supplementary Materials S.5 provides more detailed performance metrics. These results reveal that the proposed model successfully captures and estimates the waning trend of the VEs.



Figure 3 Simulation results when VE wanes over time: average VE estimates (asterisks) with (2.5%, 97.5%) quantile intervals (vertical bars) across 600 cohorts of the PWP-GT frailty model.

In summary, the proposed PWP-GT frailty model demonstrated satisfactory performance for both constant VE and waning VE. Compared to conventional VE estimation methods, this model achieves smaller bias and better 95% CI coverage via proper handling of recurrent infections and time-varying vaccine status.

National COVID Cohort Collaborative (N3C) Real Data Analysis

We applied the proposed PWP-GT frailty model to the National COVID Cohort Collaborative (N3C) datasets [31]. The N3C platform, developed as a centralized repository, aggregates electronic health record (EHR) data of COVID-19 testing records from healthcare centers across the United States. It represents one of

the most extensive and reliable multicenter databases for COVID-19 testing records in real-world settings. More details about the N3C platform are provided in Supplementary Materials S.7.

This analysis focused on estimating the VE of the Pfizer-BioNTech COVID-19 mRNA vaccine (BNT162b2) against Omicron-related initial infection and reinfection of SARS-CoV-2. As the N3C dataset does not uniformly specify infection variants, Omicron-related infections were identified by considering infection events in the dataset from December 1, 2021, when the first U.S. case attributed to the Omicron variant was reported, up to April 02, 2024. The VE was evaluated for both the short-term (14-180 days) and long-term (greater than 180 days) periods following the administration of the full doses (2 doses) and the full doses plus the first booster dose (3 doses).

Following the data processing steps (Supplementary Materials S.8), the final dataset consists of 212,887 subjects eligible for inclusion in this analysis. Among these, 133,822 are females and 79,065 are males. All subjects received the full doses of the BNT162b2 vaccine, with 78,998 (37%) receiving the booster dose. In terms of infection status of the Omicron variants, 155,449 individuals were never infected, 56,204 had only the initial infection, and 1,208 experienced reinfections. The distribution plots of age, location (state), infection time, and vaccination time in the final dataset are provided in Supplementary Materials S.9.

In the PWP-GT frailty model, we adjusted gender, age groups, race, and pre-Omicron infection status as time-independent covariates. To account for the risk of infection, we divided it into internal and external components. The internal risk of infection is captured by the gap-time scale in the model, which is independent of calendar time and determined solely by the individual (e.g., internal immunity). To represent the external risk of infection (e.g., community spread), we included time-specific case numbers (updated every four months) as a time-dependent covariate. Additionally, a frailty term was incorporated at the location level (state), instead of subject level, to account for within-location correlation, recognizing that reinfection is relatively rare. Supplementary Materials S.8 gives more detailed information about the model set-up. The analysis codes and outputs are available upon request within the N3C Enclave (https://covid.cd2h.org/enclave/) under Project ID RP-7FEF96.

Table 1 presents the estimated VEs of the full doses and the booster dose against Omicron-related initial infection and reinfection, evaluated at 14-180 days and beyond 180 days post-vaccination. The table also includes the associated 95% CI and standard errors of the VE estimates. For the initial Omicron-related infection, the full doses of the BNT162b2 vaccine demonstrates a VE of 25.80% within 14-180 days following vaccination, which decreased moderately to 19.03% after 180 days. The booster dose was associated with a VE of 52.11% within 180 days of boosting, but its effectiveness declined sharply to 9.88% after six months. This substantial drop is likely due to the long time since vaccination of individuals within the 180+ days group (average ~400 days). Regarding the Omicron-related reinfection, the VE of the full doses was 73.48% within the six-month vaccination window, with a slight decline to 68.71% beyond 180 days. The VE estimates of the booster dose against reinfection are comparable to those of the full doses, 72.94% for the first 14-180 day and 65.05% beyond six months since the boosting. No significant violation of the proportional hazards assumption was detected in the graphs of the scaled Schoenfeld residuals.

Table 1 VE estimation results in N3C data analysis

Infection	Regimes (# Doses)	Vaccination Period	VE (95% CI)	SE(VE)
Initial infection	Full doses (2)	14-180 days	24.80% (21.25% - 28.35%)	1.81%
Initial infection	Full doses (2)	180+ days	19.03% (15.39% - 22.67%)	1.86%
Initial infection	Booster dose (3)	14-180 days	52.11% (49.67% - 54.55%)	1.25%
Initial infection	Booster dose (3)	180+ days	9.88% (5.26% - 14.50%)	2.36%
Reinfection	Full doses (2)	14-180 days	73.48% (55.09% - 91.87%)	9.38%
Reinfection	Full doses (2)	180+ days	68.71% (52.84% - 84.58%)	8.10%
Reinfection	Booster dose (3)	14-180 days	72.94% (55.49% - 90.39%)	8.90%
Reinfection	Booster dose (3)	180+ days	65.05% (47.04% - 83.05%)	9.19%

Note:
(a) This analysis is based on testing records of 212,887 subjects in N3C datasets.
(b) The reference group is the unvaccinated group.
(c) Booster dose represents the total protection of full doses plus one booster dose.

These estimates are similar to those in the literature [11,32–34] and comprehensive meta-analyses [3]. Our results show that in real-world settings, 3 doses of the BNT162b2 vaccine were able to protection against Omicron-related medically-attended symptomatic infections for up to six months, and both the full doses and

the booster dose offered high levels of short- and long-term protection against subsequent infections among people had experienced an initial Omicron-related infection.

Discussion

Unlike traditional case-control studies or other outcome-driven sampling design frameworks, TND studies randomly sample individuals presenting clinical symptoms who are to be tested for a pathogen, making them more analogous to cohort studies within a subpopulation. In this study, we proposed a novel use of the PWP-GT frailty model in TND studies to address recurrent time-to-event outcomes, individual level heterogeneity, and time-dependent vaccination status. Our simulation studies demonstrated that the proposed model yields less biased VE estimates and better nominal coverage probability of confidence intervals, compared to traditional VE estimation models commonly used in TND studies. Furthermore, we applied the model to the N3C dataset for estimating real-world effectiveness of full and boosting doses of Pfizer's COVID-19 mRNA vaccine against subsequent infections, and our results are in line with existing estimates.

The TND remains a relatively new study design, and its unique structure makes it susceptible to various sources of confounding and biases that require careful consideration[8,35–39]. This work introduces survival models as a powerful alternative to traditional logistic regression approaches, offering significant advantages in addressing recurrent infections and dynamic vaccination history. The survival models better capture the dynamics of both infection risks and vaccine status (which is a time-dependent variable) at the individual level, which is the major reason for them to outperform the logistic regressions. For the logistic regressions (CL-TND, ULA-TND and UL-TND), an individual contributes to the likelihood or conditional likelihood only for the times he/she was tested. In contrast, in the survival models, an individual contributes to the partial likelihood for each event time regardless of whether he/she was tested at that time or not, as long as he/she was considered at risk at that time point (i.e., before a positive test of the target event). There could be other minor reasons, for instance, the frailties in the PWP-GP models better capture the correlation of events within each individual, whereas the logistic models treat the two infections as independent events. Our simulation results also underscore the importance of appropriately accommodate calendar time when using

logistic regression to estimate ORs in TND studies, to avoid severe bias, consistent with the existing literature[40].

Furthermore, the adoption of survival analysis opens new avenues for TND studies to capture nuanced temporal dynamics of infection and immunity, including time-varying infection hazards and waning vaccine effectiveness, which are increasingly critical for optimizing vaccination strategies and other public health interventions in the context of rapid evolution of pathogens and population landscape of immunity. This approach also facilitates meta-analysis of VE across multiple types of studies. Traditionally, it is challenging to combine VE estimates based on hazard ratios from cohort studies and those based on odds ratios from TND studies[3]. Although OR approximates RR in many situations, RR does not necessarily approximate HR unless cumulative hazards associated with RR are small, which may not be always true. In addition, for conditional logistic regression to produce OR close to HR, the at-risk set at each case time should be formed as in a Cox regression, i.e., each enrolled person should enter the at-risk set at all case times up to his/her own infection (positive test) or censoring (last negative test), which is not necessarily a routine practice in most TND studies. Consequently, pooling HR- and OR-based VE estimates requires either common effect scales (e.g., re-estimating TND with a hazard model) or separate meta-analyses for different effect-measure types. The capacity of TND studies to contribute hazard-based estimates will greatly enrich the data sources for more reliable VE meta-analysis.

In this work, we adopted the classic TND in which all eligible and enrolled individuals were included in the analyses. If a subset of controls is to be sampled or matched to the case at each event time, the TND essentially becomes a NCC design. Conditional logistic regression has been widely applied to NCC studies, and it can be shown that the estimated odds ratios provide close approximation to the hazard ratios under mild conditions [41]. However, it remains to be investigated whether the approximation works well in the presence of frailties

There are at least two potential extensions of our models for broader applications. First, VE could be modeled as varying continuously over time. While a piecewise approach is generally sufficient to capture the waning effectiveness in most cases, a continuous-time framework provides a more complete picture at a finer

resolution. This can be achieved using time-varying coefficients, e.g., through smoothing splines, which are widely used in survival analysis. In addition, Bayesian methods can be employed to incorporate external information from literature on the temporal pattern of immune responses. Second, for certain infectious diseases where the risk of infection is strongly influenced by the cumulative hazard over the total time rather than the interval between two consecutive events, the gap-time scale could be replaced by the total-time scale. This adjustment may better reflect how immunity jumps and wanes in response to multiple infections or immunization events.

Despite these promising results, our work has several limitations and practical guidance. First, as an inherent limit in the TND, the method is based on a subpopulation of individuals seeking medical care, and extending these VE estimates from TND studies to the general population requires additional data sources or assumptions, e.g., to obtain VE against infection, we need the probability of seeking medical attention given infection. Second, similar to Cox regression models applied to observational studies in general, causal interpretation cannot be reached for the VE estimated by the proposed model within TND studies, as unmeasured confounders are difficult to control for in the absence of randomization, and Cox hazard ratios are not causally interpretable[42,43]. Third, we did not consider the impact of possible prior infection by earlier variants before the Omicron era in the data analysis. In addition, as we relied on EHR to identify Omicron infection histories, a certain number of asymptomatic and subclinical infections that did not lead to medical visits could have occurred among the study subjects but were missing in our analysis. These undetected infections could have altered the immune response and hence affected the VE estimates. However, it has been well documented that the effectiveness of BNT162b2 against any infection (regardless of symptoms) is relatively low[44–46]. Henceforth, the undetected infections likely equally affected people with different vaccination histories and the resulting impact on our estimates of VE against medically attended and tested infections is perhaps minor. Moreover, our PWP-GT frailty framework is specifically designed for scenarios where reinfections are fairly frequent. When recurrent infections are rare, for example, a single epidemic season of influenza [47,48], the proposed framework reduces to the regular Cox regression with frailties. Finally, our assumption of no social effect of the vaccine of interest on nuisance pathogens may be overly strong in

some situations, e.g., elderly people vaccinated against the SARS-CoV-2 are probably more likely to be vaccinated against influenza, and healthcare workers are often required to be vaccinated against multiple pathogens.

In summary, the applicability of advanced survival models to TND studies provides more reliable estimates of vaccine effectiveness under real-world conditions and thereby better informs public health decision-making. We call for methodological research and data collection regarding potential confounders that affect behaviors related to exposure, vaccination, health-seeking, and testing to improve causal interpretation of VE estimates based on TND studies.

References

1. Skowronski DM, Masaro C, Kwindt TL, et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: Results from the 2005–2006 season of dual A and B vaccine mismatch in Canada. *Vaccine*. 2007;25(15):2842-2851. doi:10.1016/j.vaccine.2006.10.002

2. Chua H, Feng S, Lewnard JA, et al. The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology. *Epidemiology*. 2020;31(1):43. doi:10.1097/EDE.0000000000001116

3. Song S, Madewell ZJ, Liu M, Longini IM, Yang Y. Effectiveness of SARS-CoV-2 vaccines against Omicron infection and severe events: a systematic review and meta-analysis of test-negative design studies. *Front Public Health*. 2023;11. doi:10.3389/fpubh.2023.1195908

4. Dean NE, Hogan JW, Schnitzer ME. Covid-19 Vaccine Effectiveness and the Test-Negative Design. *New England Journal of Medicine*. 2021;385(15):1431-1433. doi:10.1056/NEJMe2113151

5. Dean N, Amin AB. Test-Negative Study Designs for Evaluating Vaccine Effectiveness. *JAMA*. 2024;332(2):163-164. doi:10.1001/jama.2024.5633

6. Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness. *American Journal of Epidemiology*. 2016;184(5):345-353. doi:10.1093/aje/kww064

7. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. *Vaccine*. 2013;31(17):2165-2168. doi:10.1016/j.vaccine.2013.02.053

8. Shi X, Li KQ, Mukherjee B. Current Challenges With the Use of Test-Negative Designs for Modeling COVID-19 Vaccination and Outcomes. *American Journal of Epidemiology*. 2023;192(3):328-333. doi:10.1093/aje/kwac203

9. Song S, Madewell ZJ, Liu M, et al. A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants. *Vaccine*. 2024;42(15):3389-3396. doi:10.1016/j.vaccine.2024.04.049

10. Hitchings MDT, Ranzani OT, Torres MSS, et al. Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study. *The Lancet Regional Health – Americas*. 2021;1. doi:10.1016/j.lana.2021.100025

11. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. *New England Journal of Medicine*. 2022;386(16):1532-1546. doi:10.1056/NEJMoa2119451

12. Sullivan SG, Khvorov A, Huang X, et al. The need for a clinical case definition in test-negative design studies estimating vaccine effectiveness. *npj Vaccines*. 2023;8(1):1-5. doi:10.1038/s41541-023-00716-9

13. Prentice RL, Breslow NE. Retrospective Studies and Failure Time Models. *Biometrika*. 1978;65(1):153-158. doi:10.2307/2335290

14. Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study. *eBioMedicine*. 2023;95. doi:10.1016/j.ebiom.2023.104734

610 15. Srivastava K, Carreño JM, Gleason C, et al. SARS-CoV-2-infection- and vaccine-induced antibody
611 responses are long lasting with an initial waning phase followed by a stabilization phase. *Immunity*.
612 2024;57(3):587-599.e4. doi:10.1016/j.immuni.2024.01.017

613 16. Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous
614 Infection. *New England Journal of Medicine*. 2022;386(13):1207-1220. doi:10.1056/NEJMoa2118691

615 17. Kim JH, Liepkalns J, Reber AJ, et al. Prior infection with influenza virus but not vaccination leaves a long-
616 term immunological imprint that intensifies the protective efficacy of antigenically drifted vaccine
617 strains. *Vaccine*. 2016;34(4):495-502. doi:10.1016/j.vaccine.2015.11.077

618 18. Houser KV, Pearce MB, Katz JM, Tumpey TM. Impact of Prior Seasonal H3N2 Influenza Vaccination or
619 Infection on Protection and Transmission of Emerging Variants of Influenza A(H3N2)v Virus in Ferrets.
620 *Journal of Virology*. 2013;87(24):13480-13489. doi:10.1128/jvi.02434-13

621 19. Fox A, Carolan L, Leung V, et al. Opposing Effects of Prior Infection versus Prior Vaccination on Vaccine
622 Immunogenicity against Influenza A(H3N2) Viruses. *Viruses*. 2022;14(3):470. doi:10.3390/v14030470

623 20. Keogh RH, Cox DR. *Case-Control Studies*. Cambridge University Press; 2014.
624 doi:10.1017/CBO9781139094757

625 21. Tan CY, Chiew CJ, Pang D, et al. Protective immunity of SARS-CoV-2 infection and vaccines against
626 medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national
627 cohort study. *The Lancet Infectious Diseases*. 2023;23(7):799-805. doi:10.1016/S1473-3099(23)00060-9

628 22. Arbel R, Wolff-Sagy Y. The superiority of bivalent over monovalent booster vaccines. *The Lancet*
629 *Infectious Diseases*. 2023;23(12):1324-1325. doi:10.1016/S1473-3099(23)00424-3

630 23. Therneau TM, Grambsch PM, Pankratz VS. Penalized Survival Models and Frailty. *Journal of*
631 *Computational and Graphical Statistics*. 2003;12(1):156-175.

632 24. Prentice RL, Williams BJ, Peterson AV. On the Regression Analysis of Multivariate Failure Time Data.
633 *Biometrika*. 1981;68(2):373-379. doi:10.2307/2335582

634 25. Box-Steffensmeier JM, De Boef S. Repeated events survival models: the conditional frailty model.
635 *Statistics in Medicine*. 2006;25(20):3518-3533. doi:10.1002/sim.2434

636 26. Cox DR. Regression Models and Life-Tables. *Journal of the Royal Statistical Society: Series B*
637 *(Methodological)*. 1972;34(2):187-202. doi:10.1111/j.2517-6161.1972.tb00899.x

638 27. Amorim LD, Cai J. Modelling recurrent events: a tutorial for analysis in epidemiology. *International*
639 *Journal of Epidemiology*. 2014;44(1):324. doi:10.1093/ije/dyu222

640 28. Therneau TM. Extending the Cox Model. In: Lin DY, Fleming TR, eds. *Proceedings of the First Seattle*
641 *Symposium in Biostatistics*. Springer US; 1997:51-84. doi:10.1007/978-1-4684-6316-3_5

642 29. Liang KY, Zeger SL. Longitudinal Data Analysis Using Generalized Linear Models. *Biometrika*.
643 1986;73(1):13-22. doi:10.2307/2336267

644 30. Therneau TM. coxme: Mixed Effects Cox Models. Published online August 23, 2024. Accessed October
645 15, 2024. https://cran.r-project.org/web/packages/coxme/index.html

646 31. Haendel MA, Chute CG, Bennett TD, et al. The National COVID Cohort Collaborative (N3C): Rationale,
647 design, infrastructure, and deployment. *Journal of the American Medical Informatics Association*.
648 2021;28(3):427-443. doi:10.1093/jamia/ocaa196

649 32. Buchan SA, Nguyen L, Wilson SE, Kitchen SA, Kwong JC. Vaccine Effectiveness of BNT162b2 Against Delta
650 and Omicron Variants in Adolescents. *Pediatrics*. 2022;150(3):e2022057634. doi:10.1542/peds.2022-
651 057634

652 33. Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of Previous Infection and Vaccination on
653 Symptomatic Omicron Infections. *New England Journal of Medicine*. 2022;387(1):21-34.
654 doi:10.1056/NEJMoa2203965

655 34. Rennert L, Ma Z, McMahan CS, Dean D. Effectiveness and protection duration of Covid-19 vaccines and
656 previous infection against any SARS-CoV-2 infection in young adults. *Nat Commun*. 2022;13(1):3946.
657 doi:10.1038/s41467-022-31469-z

658 35. Graham S, Tessier E, Stowe J, et al. Bias assessment of a test-negative design study of COVID-19 vaccine
659 effectiveness used in national policymaking. *Nat Commun*. 2023;14(1):3984. doi:10.1038/s41467-023-
660 39674-0

661 36. Wiegand RE, Fireman B, Najdowski M, Tenforde MW, Link-Gelles R, Ferdinands JM. Bias and negative
662 values of COVID-19 vaccine effectiveness estimates from a test-negative design without controlling for
663 prior SARS-CoV-2 infection. *Nat Commun*. 2024;15(1):10062. doi:10.1038/s41467-024-54404-w

664 37. Ortiz-Brizuela E, Carabali M, Jiang C, Merckx J, Talbot D, Schnitzer ME. Potential Biases in Test-Negative
665 Design Studies of COVID-19 Vaccine Effectiveness Arising from the Inclusion of Asymptomatic
666 Individuals. *American Journal of Epidemiology*. Published online August 19, 2024:kwae288.
667 doi:10.1093/aje/kwae288

668 38. Lanièce Delaunay C, Nunes B, Monge S, et al. The Potential Bias Introduced into COVID-19 Vaccine
669 Effectiveness Studies at Primary Care Level Due to the Availability of SARS-CoV-2 Tests in the General
670 Population. *Social Science Research Network*. Preprint posted online November 8, 2024.
671 doi:10.2139/ssrn.5014164

672 39. Kundu S, Ding P, Li X, Wang J. Sensitivity Analysis for the Test-Negative Design. *arXiv*. Preprint posted
673 online June 11, 2024. doi:10.48550/arXiv.2406.06980

674 40. Dean NE, Halloran ME, Longini J Ira M. Temporal Confounding in the Test-Negative Design. *American*
675 *Journal of Epidemiology*. 2020;189(11):1402-1407. doi:10.1093/aje/kwaa084

676 41. Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis
677 methodologies for analysis of time-dependent exposure. *BMC Medical Research Methodology*.
678 2005;5(1):5. doi:10.1186/1471-2288-5-5

679 42. Martinussen T. Causality and the Cox Regression Model. *Annual Review of Statistics and Its Application*.
680 2022;9(Volume 9, 2022):249-259. doi:10.1146/annurev-statistics-040320-114441

681 43. Hernán MA. The Hazards of Hazard Ratios. *Epidemiology*. 2010;21(1):13-15.
682 doi:10.1097/EDE.0b013e3181c1ea43

683 44. Young-Xu Y, Zwain GM, Izurieta HS, et al. Effectiveness of mRNA COVID-19 vaccines against Omicron and
684 Delta variants in a matched test-negative case-control study among US veterans. *BMJ Open*.
685 2022;12(8):e063935. doi:10.1136/bmjopen-2022-063935

686 45. Chin ET, Leidner D, Lamson L, et al. Protection against Omicron from Vaccination and Previous Infection
687 in a Prison System. *New England Journal of Medicine*. 2022;387(19):1770-1782.
688 doi:10.1056/NEJMoa2207082

689 46. Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2
690 Infection in Qatar. *New England Journal of Medicine*. 2021;385(24):e83. doi:10.1056/NEJMoa2114114

691 47. Möst J, Redlberger-Fritz M, Weiss G. Multiple Influenza Virus Infections in 4 Consecutive Epidemiological
692 Seasons: A Retrospective Study in Children and Adolescents. *Open Forum Infect Dis*. 2019;6(6):ofz195.
693 doi:10.1093/ofid/ofz195

694 48. Price O, Birrell FA, Mifsud EJ, Sullivan SG. Epidemiology of repeat influenza infection in Queensland,
695 Australia, 2005–2017. *Epidemiology & Infection*. 2022;150:e144. doi:10.1017/S0950268822001157

696